1. Jemal A et al: Cancer statistics, 2010. CA Cancer J Clin 60:277, 2010
2. Rogers HW et al: Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 146:283, 2010
3. Pott P: Cancer scrotic. In: Chirurgical Observations Relative to the Cataract, the Polypus of the Nose, the Cancer of the Scrotum, the Different Kinds of Ruptures, and the Mortification of the Toes and Feet. London, Hawes, Clarke, and Collins, 1775, p. 63
4. Gallagher RP et al: Chemical exposures, medical history, and risk of squamous and basal cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev 5:419, 1996
5. De Hertog S et al: Relation between smoking and skin cancer. J Clin Oncol 19:231, 2001
6. Tapio S, Grosche B: Arsenic in the aetiology of cancer. Mutat Res 612:215, 2006
7. Brown KG et al: A dose-response analysis of skin cancer from inorganic arsenic in drinking water. Risk Analysis 9:519, 1989
8. Rossman TG et al: Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: An animal model for arsenic carcinogenesis. Toxicol Appl Pharmacol 176:64, 2001
9. Burns FJ et al: Arsenic-induced enhancement of ultraviolet radiation carcinogenesis in mouse skin: A dose-response study. Environ Health Perspect 112:599, 2004
10. Penn I: Post-transplant malignancy: The role of immunosuppression. Drug Saf 23:101, 2000
11. O'Donovan P et al:
Azathioprine and UVA light generate mutagenic oxidative DNA damage.
Science 309:1871, 2005
12. Yarosh DB et al: Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 125:1020-1025, 2005
13. Vonderheid
EC et al: Long-term efficacy, curative potential, and carcinogenicity of topical
mechlorethamine chemotherapy in cutaneous T cell lymphoma.
J Am Acad Dermatol 20(3):416-428, 1989 PubMed
[PubMed: 2537348]
.
14. Roelofzen JH et al: No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. J Invest Dermatol 130:953, 2010
15. Lichter MD et al: Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol 136:1007, 2000
16. Stern RS, Liebman EJVakeva L: Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 90:1278, 1998
17. Stern RS: Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. N Engl J Med 322:1093, 1990
18. Stern RS, Nichols KT, Väkevä LH: Malignant melanoma in patients treated for psoriasis with
methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study.
N Engl J Med 336:1041-1045, 1997
19. Stern RS: Putting iatrogenic risk in perspective: basal cell cancer in PUVA patients and Australians. J Invest Dermatol 129:2315-2316, 2009
20. Nataraj AJ, Black HS, Ananthaswamy HN: Signature p53 mutation at DNA cross-linking sites in 8- methoxypsoralen and ultraviolet A (PUVA)-induced murine skin cancers. Proc Natl Acad Sci USA 93:7961, 1996
21. Harwood CA et al: Detection of human papillomavirus DNA in PUVA-associated non-melanoma skin cancers. J Invest Dermatol 111:123, 1998
22. Lee E, Koo J, Berger T: UVB phototherapy and skin cancer risk: A review of the literature. Int J Dermatol 44:355, 2005
23. Schulman JM, Fisher DE: Indoor ultraviolet tanning and skin cancer: health risks and opportunities. Curr Opin Oncol 21:144-149, 2009
24. El Ghissassi F et al: A review of human carcinogens—part D: radiation. Lancet Oncol 10:751-752, 2009
25. Fisher DE, James WD: Indoor tanning–science, behavior, and policy. N Engl J Med 363(10):901-903, 2010
26. Luch A: Nature and nurture—Lessons from chemical carcinogenesis. Nat Rev Cancer 5:113, 2005
27. Dipple A: DNA adducts of chemical carcinogens. Carcinogenesis 16:437, 1995
28. Jackson MA, Stack HF, Waters MD: The genetic toxicology of putative nongenotoxic carcinogens. Mutat Res 296:241, 1993
29. Marnett LJ: Oxyradicals and DNA damage. Carcinogenesis 21:361, 2000
30. Yuspa SH, Shields, PG: Etiology of cancer: Chemical factors. In: Cancer Principles of Oncology, 5th edition, edited by VT DeVita et al. Philadelphia, Lippincott-Raven, 1997, p. 185
31. Gonzalez F: Genetic polymorphism and cancer susceptibility: Fourteenth Sapporo Cancer Seminar. Cancer Res 55:710, 1995
32. Nebert DW, Dalton TP: The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 6:947, 2006
33. Ioannides C, Lewis DF: Cytochromes P450 in the bioactivation of chemicals. Curr Top Med Chem 4:1767, 2004
34. Bock KW, Kohle C: The mammalian aryl hydrocarbon (Ah) receptor: From mediator of dioxin toxicity toward physiological functions in skin and liver. Biol Chem 390:1225, 2009
35. Croce CM: Oncogenes and cancer. N Engl J Med 358:502, 2008
36. Foulkes WD: Inherited susceptibility to common cancers. N Engl J Med 359:2143, 2008
37. Somoano B, Niendorf KB, Tsao H: Hereditary cancer syndromes of the skin. Clin Dermatol 23:85, 2005
38. van Steeg H, Kraemer KH: Xeroderma pigmentosum and the role of UV-induced DNA damage in skin cancer. Mol Med Today 5:86, 1999
39. Cleaver JE: Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Cancer 5:564, 2005
40. de Boer J, Hoeijmakers JH: Nucleotide excision repair and human syndromes. Carcinogenesis 21:453, 2000
41. Wei Q et al: DNA repair related to multiple skin cancers and drug use. Cancer Res 54:437, 1994
42. Wood RD et al: Human DNA repair genes. Science 291:1284, 2001
43. Winsey SL et al: A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 60:5612, 2000
44. Daya-Grosjean L, Sarasin A: The role of UV induced lesions in skin carcinogenesis: An overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. Mutat Res 571:43, 2005
45. Saran A: Basal cell carcinoma and the carcinogenic role of aberrant Hedgehog signaling. Future Oncol 6:1003, 2010
46. Barakat MT, Humke EW, Scott MP: Learning from Jekyll to control Hyde: Hedgehog signaling in development and cancer. Trends Mol Med 16:337, 2010
47. Hussussian CJ et al: Germline p16 mutations in familial melanoma. Nat Genet 8:15, 1994
48. Davies H et al: Mutations of the BRAF gene in human cancer. Nature 417:949, 2002
49. Liaw D et al: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64, 1997
50. Li J et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943, 1997
51. Bapat B et al: The genetic basis of Muir-Torre syndrome includes the hMLH1 locus. Am J Hum Genet 59:736, 1996
52. Bignell GR et al: Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 25:160, 2000
53. Salhi A et al: Multiple familial trichoepithelioma caused by mutations in the cylindromatosis tumor suppressor gene. Cancer Res 64:5113, 2004
54. Nickerson ML et al: Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2:157, 2002
55. Chan EF et al: A common human skin tumour is caused by activating mutations in beta-catenin. Nat Genet 21:410, 1999
56. Takeda H et al: Human sebaceous tumors harbor inactivating mutations in LEF1. Nat Med 12:395, 2006
57. Dlugosz A, Merlino G, Yuspa SH: Progress in cutaneous cancer research. J Investig Dermatol Symp Proc 7:17, 2002
58. Oro AE et al: Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 276:817, 1997
59. Adolphe C et al: An in vivo comparative study of sonic, desert and Indian hedgehog reveals that hedgehog pathway activity regulates epidermal stem cell homeostasis. Development 131:5009, 2004
60. Xie J et al: Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 391:90, 1998
61. Grachtchouk V et al: The magnitude of hedgehog signaling activity defines skin tumor phenotype. EMBO J 22:2741, 2003
62. Fan H et al: Induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog. Nat Med 3:788, 1997
63. Goodrich LV et al: Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 277:1109, 1997
64. Hahn H et al: Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med 4:619, 1998
65. Aszterbaum M et al: Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nat Med 5:1285, 1999
66. Mancuso M et al: Basal cell carcinoma and its development: Insights from radiation-induced tumors in Ptch1-deficient mice. Cancer Res 64:934, 2004
67. Nilsson M et al: Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc Natl Acad Sci U S A 97:3438, 2000
68. Grachtchouk M et al: Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat Genet 24:216, 2000
69. Hutchin ME et al: Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: Conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev 19:214, 2005
70. Smoller BR: Squamous cell carcinoma: From precursor lesions to high-risk variants. Mod Pathol 19(Suppl 2):S88, 2006
71. Khavari PA: Modelling cancer in human skin tissue. Nat Rev Cancer 6:270, 2006
72. Lazarov M et al: CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med 8:1105, 2002
73. Dajee M et al: NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421:639, 2003
74. Friedberg
EC, Meira LB: Database of mouse strains carrying targeted mutations in genes affecting cellular responses to DNA damage. Version 4.
Mutat Res 459:243, 2000
75. Ise K et al: Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. Oncogene 19:2951, 2000
76. Quintanilla M et al: Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322:78, 1986
77. Brown K et al: The malignant capacity of skin tumours induced by expression of a mutant H-ras transgene depends on the cell type targeted. Curr Biol 8:516, 1998
78. Perez-Losada J, Balmain A: Stem-cell hierarchy in skin cancer. Nat Rev Cancer 3:434, 2003
79. Kemp CJ et al: Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74:813, 1993
80. Ahmadian A et al: Genetic instability in the 9q22.3 region is a late event in the development of squamous cell carcinoma. Oncogene 17:1837, 1998
81. Krimpenfort P et al: Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413:83, 2001
82. Sotillo R et al: Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci U S A 98:13312, 2001
83. Dankort D et al: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544, 2009
84. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57, 2000
85. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 396:643, 1998
86. Glick AB, Yuspa SH: Tissue homeostasis and the control of the neoplastic phenotype in epithelial cancers. Semin Cancer Biol 15:75, 2005
87. Kemp CJ: Multistep skin cancer in mice as a model to study the evolution of cancer cells. Semin Cancer Biol 15:460, 2005
88. Yuspa SH: The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis–Thirty-third G.H.A. Clowes Memorial Award Lecture. Cancer Res 54:1178, 1994
89. Hennings H et al: Induction of papillomas with a high probability of conversion to malignancy. Carcinogenesis 6:1607, 1985
90. Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature 411:355, 2001
91. Mueller MM: Inflammation in epithelial skin tumours: Old stories and new ideas. Eur J Cancer 42:735, 2006
92. Iversen OH: The skin tumorigenic and carcinogenic effects of different doses, numbers of dose fractions and concentrations of 7,12- dimethylbenz[a]anthracene in acetone applied on hairless mouse epidermis. Possible implications for human carcinogenesis. Carcinogenesis 12:493, 1991
93. Hennings H et al: Development of an in vitro analogue of initiated mouse epidermis to study tumor promoters and antipromoters. Cancer Res 50:4794, 1990
94. Hennings H et al: Enhanced malignant conversion of benign mouse skin tumors by
cisplatin.
J Natl Cancer Inst 82:836, 1990
95. Kemp CJ, Fee F, Balmain A: Allelotype analysis of mouse skin tumors using polymorphic microsatellites: Sequential genetic alterations on chromosomes 6, 7, and 11. Cancer Res 53:6022, 1993
96. Robertson KD, Jones PA: DNA methylation: Past, present and future directions. Carcinogenesis 21:461, 2000
97. Zackheim HS: Experimental basal cell carcinoma in the rat. In: Models in Dermatology, edited by L Maibach. Basel, Karger, 1985, p. 89
98. Johnson WD et al: Dehydroretronecine-induced skin tumors in mice. J Natl Cancer Inst 61:85, 1978
99. Tschen JP et al: Pleomorphic basal cell carcinoma: Case reports and review. South Med J 99:296, 2006
100. Sneddon JB et al: Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci U S A 103:14842, 2006
101. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463, 2001
102. Bigelow RL et al: Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1. J Biol Chem 279:1197, 2004
103. Regl G et al: Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2. Cancer Res 64:7724, 2004
104. Ponten F et al: Epithelial-stromal interactions in basal cell cancer: The PDGF system. J Invest Dermatol 102:304, 1994
105. Xie J et al: A role of PDGFRalpha in basal cell carcinoma proliferation. Proc Natl Acad Sci U S A 98:9255, 2001
106. Kasper M et al: Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. Mol Cell Biol 26:6283, 2006
107. Fan H, Khavari PA: Sonic hedgehog opposes epithelial cell cycle arrest. J Cell Biol 147:71, 1999
108. Barnes EA et al: Patched1 interacts with cyclin B1 to regulate cell cycle progression. EMBO J 20:2214, 2001
109. Kenney AM, Rowitch DH: Sonic hedgehog promotes G(1) cyclin expression and sustained cell cycle progression in mammalian neuronal precursors. Mol Cell Biol 20:9055, 2000
110. Mill P et al: Shh controls epithelial proliferation via independent pathways that converge on N-Myc. Dev Cell 9:293, 2005
111. Yang SH et al: Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling. Nat Genet 40:1130, 2008
112. Angel JM, Caballero M, DiGiovanni J: Identification of novel genetic loci contributing to 12-O-tetradecanoylphorbol-13-acetate skin tumor promotion susceptibility in DBA/2 and C57BL/6 mice.
Cancer Res 63(11):2747-2751, 2003 PubMed
[PubMed: 12782578]
.
113. Mock BA et al: Multigenic control of skin tumor susceptibility in SENCARA/Pt mice.
Carcinogenesis 19(6):1109-1115, 1998 PubMed
[PubMed: 9667751]
.
114. Mahler KL et al: Sequence divergence of Mus spretus and Mus musculus across a skin cancer susceptibility locus. BMC Genomics 9:626, 2008 PubMed PMID: 19105829; PubMed Central PMCID: PMC2628916.
115. Wakabayashi Y et al: Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice.
Nature 445(7129):761-765, 2007 Epub 2007 Jan 17. PubMed
[PubMed: 17230190]
.
116. Dominey AM et al: Targeted overexpression of transforming growth factor a in the epidermis of transgenic mice elicits hyperplasia, hyperkeratosis, and spontaneous squamous papillomas. Cell Growth Differ 4:1071, 1993
117. Vassar R, Hutton ME, Fuchs E: Transgenic overexpression of transforming growth factor a bypasses the need for c-Ha-ras mutations in mouse skin tumorigenesis. Mol Cell Biol 12:4643, 1992
118. Hansen LA et al: The epidermal growth factor receptor is required to maintain the proliferative population in the basal compartment of epidermal tumors. Cancer Res 60:3328, 2000
119. Sibilia M et al: The EGF receptor provides an essential survival signal for SOS- dependent skin tumor development. Cell 102:211, 2000
120. Kiguchi K et al: Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. Oncogene 19:4243, 2000
121. DiGiovanni J et al: Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion. Cancer Res 60:1561, 2000
122. Skobe M, Fusenig NE: Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc Natl Acad Sci U S A 95:1050, 1998
123. Pierce AM et al: Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc Natl Acad Sci U S A 95:8858, 1998
124. Robles AI et al: Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 12:2469, 1998
125. Rane SG et al: Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol Cell Biol 22:644, 2002
126. Guasch G et al: Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell 12:313, 2007
127. Hoot KE et al: Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. J Clin Invest 118:2722, 2008
128. Harradine KA et al: Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients. Clin Cancer Res 15:5101, 2009
129. Reddig PJ et al: Transgenic mice overexpressing protein kinase Cdelta in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13- acetate. Cancer Res 59:5710, 1999
130. Jansen AP et al: Protein kinase C-epsilon transgenic mice: A unique model for metastatic squamous cell carcinoma. Cancer Res 61:808, 2001
131. Gonzalez-Suarez E et al: Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat Genet 26:114, 2000
132. Pelengaris S et al: Reversible activation of c-Myc in skin: Induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 3:565, 1999
133. Waikel RL et al: Deregulated expression of c-Myc depletes epidermal stem cells. Nat Genet 28:165, 2001
134. Missero C et al: The absence of p21 Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev 10:3065, 1996
135. Weinberg WC et al: Genetic deletion of p21WAF1 enhances papilloma formation but not malignant conversion in experimental mouse skin carcinogenesis. Cancer Res 59:2050, 1999
136. Glick AB et al: Targeted deletion of the TGF-b1 gene causes rapid progression to squamous cell carcinoma. Genes Dev 8:2429, 1994
137. Go C, Li P, Wang XJ: Blocking transforming growth factor b signaling in transgenic epidermis accelerates chemical carcinogenesis: A mechanism associated with increased angiogenesis. Cancer Res 59:2861, 1999
138. Portella G et al: Transforming growth factor b is essential for spindle cell conversion of mouse skin carcinoma in vivo: Implications for tumor invasion. Cell Growth Differ 9:393, 1998
139. Han G et al: Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Invest 115:1714, 2005
140. Perez-Lorenzo R et al: Transforming growth factor beta1 enhances tumor promotion in mouse skin carcinogenesis. Carcinogenesis 31:1116, 2010
141. Young MR et al: Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci U S A 96:9827, 1999
142. Saez E et al: c-fos is required for malignant progression of skin tumors. Cell 82:721, 1995
143. Gerdes MJ et al: Activator protein-1 activity regulates epithelial tumor cell identity. Cancer Res 66:7578, 2006
144. Clifford A et al: Role of ornithine decarboxylase in epidermal tumorigenesis. Cancer Res 55:1680, 1995
145. Linardopoulos S et al: Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. Cancer Res 55:5168, 1995
146. Navarro P et al: A role for the E-cadherin cell-cell adhesion molecule during tumor progression of mouse epidermal carcinogenesis. J Cell Biol 115:517, 1991
147. Chan KS et al: Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 114:720, 2004
148. Oskarsson T et al: Skin epidermis lacking the c-Myc gene is resistant to Ras-driven tumorigenesis but can reacquire sensitivity upon additional loss of the p21Cip1 gene. Genes Dev 20:2024, 2006
149. Proweller A et al: Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res 66:7438, 2006
150. Kobielak A, Fuchs E: Links between alpha-catenin, NF-kappaB, and squamous cell carcinoma in skin. Proc Natl Acad Sci U S A 103:2322, 2006
151. Budunova IV et al: Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis. Oncogene 18:7423, 1999
152. Li AG et al: Smad3 knockout mice exhibit a resistance to skin chemical carcinogenesis. Cancer Res 64:7836, 2004
153. Nagase H et al: Distinct genetic loci control development of benign and malignant skin tumours in mice. Nat Genet 10:424, 1995
154. Nagase H, Mao JHBalmain A: A subset of skin tumor modifier loci determines survival time of tumor- bearing mice. Proc Natl Acad Sci U S A 96:15032, 1999
155. Quigley D, Balmain A: Systems genetics analysis of cancer susceptibility: From mouse models to humans. Nat Rev Genet 10:651, 2009
156. Ewart-Toland A et al: Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 34:403, 2003
157. Long DJ et al: NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res 60:5913, 2000
158. Girardi M et al: Regulation of cutaneous malignancy by gammadelta T cells. Science 294:605, 2001
159. Nelson H et al: The XRCC1 Arg399Gln polymorphism, sunburn, and non-melanoma skin cancer: Evidence of gene-environment interaction. Cancer Res 62:152, 2002
160. Lear JT et al: Detoxifying enzyme genotypes and susceptibility to cutaneous malignancy. Br J Dermatol 142:8, 2000
161. Ramachandran S et al: Susceptibility and modifier genes in cutaneous basal cell carcinomas and their associations with clinical phenotype. J Photochem Photobiol B 63:1, 2001
162. Ljungman M: Individual variation in p53 responsiveness. J Natl Cancer Inst 93:82, 2001
163. Wright TI, Spencer JM, Flowers FP: Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol 54:933, 2006
164. Fischer SM et al: Chemopreventive activity of
celecoxib, a specific cyclooxygenase-2 inhibitor, and
indomethacin against ultraviolet light-induced skin carcinogenesis.
Mol Carcinog 25:231, 1999
165. Takigawa M et al: Inhibition of mouse skin tumor promotion and of promoter- stimulated epidermal polyamine biosynthesis by - difluoromethylornithine. Cancer Res 43:3732, 1983
166. Harwood CA et al: Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol 141:456-464, 2005
167. Darwiche N et al: Mouse skin tumor progression results in differential expression of retinoic acid and retinoid X receptors. Cancer Res 55:2774, 1995
168. Xu XC et al: Progressive decreases in nuclear retinoid receptors during skin squamous carcinogenesis. Cancer Res 61:4306, 2001
169. Birt DF et al: High-fat diet blocks the inhibition of skin carcinogenesis and reductions in protein kinase C by moderate energy restriction. Mol Carcinog 16:115, 1996
170. Black HS et al: Effect of a low-fat diet on the incidence of actinic keratosis. N Engl J Med 330:1272, 1994
171. Gupta S, Mukhtar H: Chemoprevention of skin cancer through natural agents. Skin Pharmacol Appl Skin Physiol 14:373, 2001
172. Eklind J et al:
Imiquimod to treat different cancers of the epidermis.
Dermatol Surg 29:890, 2003
173. Yarosh D et al: Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: A randomised study. Xeroderma Pigmentosum Study Group. Lancet 357:926, 2001
174. Flaherty KT et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809, 2010
175. Taipale J et al: Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406:1005, 2000
176. Scales SJ, de Sauvage FJ: Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 30:303, 2009
177. Von Hoff DD et al: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361:1164, 2009
178. Dlugosz AA, Talpaz M: Following the hedgehog to new cancer therapies. N Engl J Med 361:1202, 2009